At the end of the 96-week study those taking exenatide, sold under the brand Bydureon in the UK, saw no benefits compared to the placebo group. Experts were unsure why this was the case ...

"Vivani begins exenatide implant trial for obesity in Australia" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been ...

Exenatide ext-rel 2mg; susp for SC inj; contains sucrose. Exenatide activates the GLP-1 receptor, thereby increasing intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...